On-Demand Webinar – Promotional Strategies

Via MMIT: 76% of HCPs surveyed indicated that information received digitally has at least once impacted their prescribing decisions. Yet, only 31% of HCPs surveyed have ever received drug coverage information digitally. Utilize Skipta’s social network, where verified HCPs collaborate and learn to reach medical professionals with timely messaging.

Case Study: SkiptaNXT Triggered Messaging

Download the case study to learn how Skipta helped a pharma company in the rare-disease space drive engagement with target HCPs using videos to complement their brand website promotion strategy.

2024 Indices Survey

Via MMIT: 76% of HCPs surveyed indicated that information received digitally has at least once impacted their prescribing decisions. Yet, only 31% of HCPs surveyed have ever received drug coverage information digitally. Utilize Skipta’s social network, where verified HCPs collaborate and learn to reach medical professionals with timely messaging.

Infographic: MMIT/Skipta PP and NPP

Download this infographic to see how Skipta and MMIT provide four promotional HCP engagement solutions that can help improve your brand awareness to your brand’s target medical professionals.

Case Study: Skipta’s Video Showcase

Download the case study to learn how Skipta helped a pharma company in the rare-disease space drive engagement with target HCPs using videos to complement their brand website promotion strategy.

Timing Is Everything: 4 Trends to Bolster Your HCP Marketing Strategy

In the past few years, it’s become more challenging for pharmaceutical companies to promote their products directly to healthcare providers (HCPs), and COVID only exacerbated this trend. Physicians are more selective in who they choose to meet with, and many no longer accept face-to-face meetings with pharmaceutical reps.

Why pharma should invest in evidence-based physician education

For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. Today’s molecular-targeted therapies have very different treatment paradigms, not to mention cost structures.